Fig. 5

The secretome derived from perinatal MSCs promotes cell proliferation via the PI3K/AKT pathway. A HaCaT and HUVEC cells were treated with secretome derived from hUCMSCs, hCVMSCs, or hDCMSCs for the indicated time points. Representative western blot images and quantification showed changes in the expression levels of p-AKT and Cyclin D1. B Cell viability of HaCaT and HUVEC cells treated with secretome derived from hUCMSCs, hCVMSCs, or hDCMSCs in the presence or absence of the AKT inhibitor AT7867 (5 μM) or the PI3K inhibitor LY294002 (50 μM); C Representative immunofluorescent staining images and quantification of Ki67-positive HaCaT and HUVEC cells following 4 days of inhibitor treatment (scale bar = 100 μm). Experiments were repeated at least three times, and quantification data represented mean ± SD, *, **, and *** represent p<0.05, 0.01, and 0.001 by Tukey’s post-hoc test when statistical significance by One-way ANOVA(p < 0.05) is obtained